skip to Main Content

Drug combination yields highest response and longest survival rates for patients with pancreatic NETs

Newsfeed image, light gray text on dark gray background
Very few treatment options are available to patients with advanced pancreatic neuroendocrine tumors (NETs), but researchers at the Yale Cancer Center and Yale New Haven Health’s Smilow Cancer Hospital found that patients treated with a combination of capecitabine and temozolomide had longer progression-free survival rates than those treated with temozolomide alone. The findings will be presented on June 5 at the 2022 Annual Meeting of the American Society of Clinical Oncology (ASCO).

The trial was a randomized, phase 2 clinical trial comparing the effects of temozolomide alone with those of temozolomide in combination with capecitabine. The trial, which included 144 patients, showed that the combination of capecitabine and temozolomide produced longer progression-free survival rates, higher response rates, and longer overall survival rates than temozolomide alone. In addition, deficiency of the DNA repair enzyme methylguanine methyltransferase (MGMT) in the tumor tissue, was found to be associated with increased responses  Read more . . . 

Back To Top